Developing Novel Gamma Delta T Cell Engager Therapies; CYT X300 a Pan Gamma Delta T Cell Engager Targeting EGFR Positive Solid Tumours

• Cytospire is developing next generation T-cell engagers targeting γδ T-cells
• Our engagers are designed to enhance and direct key effector cells of the innate and adaptive immune system, providing a safer alternative to CD3 based engagers
• In the presentation I will describe preclinical data supporting development of CYT X300, a first-in-class pan-gamma delta T-cell engager targeting EGFR

Speakers:

James Legg

Chief Scientific Officer

Cytospire Therapeutics Ltd